Genaissance Pharmaceuticals, Inc. develops and uses genetic information to diagnostic and therapeutic products. The company was founded by Kevin L. Rakin and Gualberto Ruano in 1992 and is headquartered in New Haven, CT.

SurExam Bio-Tech Co., Ltd. provides personalized medical system solutions focused on tumor molecular diagnostic products and clinical medicine testing services. Its products include medical kits, as well as it provides medical testing services. The company was founded on November 28, 2006 and is headquartered in Guangzhou, China.

Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.

Zhenjiang First People's Hospital is a Chinese private company located in Zhenjiang that provides healthcare services.

Sirna Therapeutics, Inc. was a San Francisco, California based biotechnology company that explored the use of RNA interference in human disease therapy. Sirna's development pipeline includes several small interfering RNA (siRNA) drugs, thought to stably silence the expression of specific disease-related genes. Sirna's clinical trial of an siRNA-based treatment for age-related macular degeneration is the first such trial for an siRNA drug.

Ractigen Therapeutics is a Chinese company located in Nantong that engages in research and development of innovative drugs and disease treatment methods. It was founded in 2016. Li Longcheng is currently the CEO of the firm.\nThe company says this about itself: Ractigen Therapeutics was founded in 2017 by pioneers of the RNA activation (RNAa) technology including Dr. Long-Cheng Li and his longstanding colleagues Dr. Robert Place and Dr. Moorim Kang. Ractigen is a late-stage preclinical pharmaceutical company devoted to creating groundbreaking therapies based on oligonucleotide technologies including RNAa and RNAi. Supporting therapeutic development, Ractigen Therapeutics has also created a portfolio of delivery platforms including its SCAD system, which allows enhanced biodistribution throughout CNS and empowers a pipeline of first-in-class candidate medicines for patients with unmet genetic disorders. The Company recently completed +$50M Series A/A+ venture financing rounds with participation from reputed investors including SDIC Venture Capital, Hillhouse Venture Capital, Eisai Co., LC Ventures, CSSD Capital, Xianghe Capital, CCB Healthcare Growth Fund, Boyi Capital, and Longman Capital.

China Medical Data Technology (Beijing) Co., Ltd., established on 2014-11-13, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;software development;Office Equipment Sales;Machinery sales;Production of protective equipment for medical personnel(Ι class medical device).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Class III medical device business;Production of protective equipment for medical personnel(Class II medical device).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)(Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

Oncotherapy science (OTS) is“ to deliver cancer therapeutics and treatments with higher efficacy and fewer side effects to patients suffering from cancer as soon as possible, and to overcome the fight against cancer. Was established with the aim of OTS brought Professor Genomix (Science that handles genetic information systematically) as a pioneer in the medical field with Prof. Atsushi Nakamura (Director, Cancer Precision Medical Research Center, Institute of Cancer, Professor Emeritus, The University of Tokyo, Professor Emeritus of Chicago University) Joint research to identify target molecules suitable for cancer drug development based on comprehensive gene expression analysis, and promote research and development of small molecule drugs, cancer peptide vaccines and antibody drugs for those targets.

Beijing Yihuo Biotechnology Co., Ltd., established on 2015-10-16, Business scope includes technology development,Technology Promotion,Technical Services,technical consulting;Natural science research and experimental development;Medical Research and Experimental Development;Engineering and Technology Research and Experimental Development;software development;Technical testing;Import and export,Technology Import and Export;Sell ​​self-developed products,cosmetic,hygiene products,medical instrumentsI,II;hygiene products,Chemical Products(Does not contain dangerous chemicals and a class of precursor chemicals),metal products,Electronic Component,Instrumentation;sell food;Sales of medical devicesIIIkind;retail medicine.(Enterprises independently choose operating projects according to law,Carry out business activities;retail medicine,Sales of Class III medical devices and items subject to approval according to law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

Zhejiang Cancer Hospital is a Chinese private company located in Hangzhou. The firm operates as an cancer hospital.

Shenji Bio focuses on the research and development of fundamental raw materials such as nucleosides, nucleotides, diagnostic antigens, and antibodies. As a development direction, Shenji Bio provides cost-effective products and addresses clinical unmet needs. It has gradually entered the upstream core raw material fields of IVD, mRNA, CGT, and other industries, and has established a high-quality key common technology platform to provide overall solutions for the life science field's development.

Jiangsu Bojia Biomedical Technology Co., Ltd., established on 2021-04-02, Business scope includes licensed projects:Production of Class III Medical Devices;Class III medical device business;Veterinary drug production;Quality and safety inspection of agricultural products;Production of Class II Medical Devices;Forestry product quality inspection and testing;Quality inspection of edible fungi;Forest grass seed quality inspection;Crop Seed Quality Inspection;Entry-Exit Quarantine Processing;Import and export commodity inspection and appraisal;Inspection and testing service;Safety production inspection and testing;Indoor environment detection;patent agency;Veterinary drug business;Cosmetic production;Disinfectant production(Free of Hazardous Chemicals);Production of hygiene products and single-use medical products(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;R&D and application of cell technology;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Water Environment Pollution Prevention and Control Services;Atmospheric Environmental Pollution Prevention and Control Services;Agricultural non-point source and heavy metal pollution prevention and control technical services;Indoor Air Pollution Control;Agricultural Science Research and Experimental Development;Medical Research and Experimental Development;Vector Biodensity Control Level Evaluation Service;Vector Biodensity Monitoring and Evaluation Service;Development of Human Gene Diagnosis and Therapy Technology;R&D of industrial enzyme preparations;Fermentation process optimization technology research and development;Technology intermediary service;New material technology promotion service;New material technology research and development;Vector biological control services;Animal Husbandry Professional and Auxiliary Activities;Sales of air pollution monitoring and testing instruments;Sales of water pollutant monitoring and testing instruments;Manufacturing of ecological environment monitoring and testing instruments;internet sales(Except for products that require a license for sale);Sales of hygiene products and single-use medical products;Specialty Chemicals Sales(Free of Hazardous Chemicals);Experimental analysis instrument sales;Glassware Sales;Retailing of protective equipment for healthcare workers;Cosmetics Wholesale;Disinfectant sales(Free of Hazardous Chemicals)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Guangzhou Kingmed Center For Clinical Laboratory Co., Ltd. provides clinical and laboratory testing services. It offers clinical trials, medical examination, food and hygiene testing, physical examination, scientific research services, and quality management. The company was founded by YaoMing Liang in 1994 and is headquartered in Guangzhou, China.

Moogene Medi Co., Ltd. engages in the development of medicine and pharmacy. It develops nanomaterials and nanotechnology for gene therapy. The company was founded on June 22, 2016 and is headquartered in Hanam-si, South Korea.

ST PHARM is a family company of the Dong-A Sosio Group, which has a history of 80 years in the domestic market . It produces excellent APIs with the mission of 'endless challenge for human health and happiness' I want to. The company is pursuing contract development and manufacturing (CDMO) projects that involve research and development with global pharmaceutical companies, beyond simple consignment production. Through accumulated research and technological expertise, They supply raw material pharmaceuticals to domestic and overseas pharmaceutical companies. In addition, through active investment and system construction, they are operating an international quality and production system certified by cGMP from regulatory agencies such as US FDA, EMA, as well as MFDS in Korea. In the meantime, as a result of constant investment and technological development, the company has been selected as an Advanced Technology Center (ATC), an innovative pharmaceutical company, and a World Class 300 company. Have been recognized.

Schering AG was a research-centered German multinational pharmaceutical company headquartered in Wedding, Berlin, which operated as an independent company from 1851 to 2006. In 2006 it was bought by Bayer AG and merged to form the Bayer subsidiary Bayer Schering Pharma AG, which was renamed Bayer HealthCare Pharmaceuticals in 2011. Schering was listed on the Frankfurt Stock Exchange and had 26,000 employees as of 2004.

Shanghai Jikai Gene Technology Co., Ltd., established on 2013-09-22, Business scope includes gene technology,Biotechnology,Technology development in the field of biotechnology,technology transfer,technical consulting,Technical Services,Genetic Testing,business inquiries,Laboratory consumables and reagents,Sales of laboratory instruments,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Suzhou Jikai Gene Technology Co., Ltd., established on 2009-09-25, Business scope includes research on new drug technology and products,to develop,Technical Services;New drug technology transfer;Gene,biology,Technology development in the field of biochemistry,technology transfer,technical consulting,Technical Services,Technical Training;Biomedical Service Outsourcing;business inquiries;Laboratory consumables and reagents,Instrument sales;Engaged in the import and export of goods and technology.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Changsha Aidikang Medical Laboratory Co., Ltd., established on 2010-04-19, The scope of business includes clinical cytomolecular genetics;clinical serology major;clinical immunology major;clinical chemistry laboratory;clinical microbiology major;Clinical Hematology;clinical body fluids;Class I medical device retail;Self-operated and agent import and export of various commodities and technologies,Except for the goods and technologies that the state restricts the company to operate or prohibits the import and export of;computer software sales;Research and Development of Communication Technology;Computer Network System Engineering Services;Information Technology Consulting Services;Pathology;General cargo transportation(freight rental,Except for moving transportation);Dedicated transport of goods(Refrigerated).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Do not engage in unauthorizedP2Ponline loan,Equity crowdfunding,internet insurance,Asset management and cross-border finance,Third party payment,virtual currency transaction,ICO,Internet financial services such as illegal foreign exchange)